The company has significantly boosted the development of an new solution for cardiac amyloidosis, leveraging the investigational drug. Initial patient data indicates potential improvements for those diagnosed from a https://biotech968424.designi1.com/62849374/company-improves-amyloidosis-treatment-using-the-drug